Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Acceptance Lettter - Corifact

Our STN: BL 125385/0                                                                                  

CSL Behring GmbH
Attention:  Mr. Paul R. Hartmann
1020 First Avenue, P.O. Box 61501
King of Prussia, PA  19406-0901

Dear Mr. Hartmann:

We have reviewed your submission dated August 18, 2010 to your biologics license application (BLA) for Factor XIII Concentrate (Human) requesting a proprietary name review. 

In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB) we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, Corifact, is acceptable at this time.

If you have any questions, please contact Ms. Nannette Cagungun at (301) 827-6174.

Sincerely yours,

Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics
Evaluation and Research

Resources for You

Page Last Updated: 09/23/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English